Pro and con: Low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management

American Journal of Cardiology

Volumn 87, Issue 5 SUPPL. 1, 2001, Pages 8-12

  Pedersen, Terje R ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTRITIS; HEADACHE; HEPATITIS; HUMAN; INSOMNIA; MYALGIA; PRIORITY JOURNAL; SECONDARY PREVENTION;

EID: 0035825934     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(01)01449-7     Document Type: Conference Paper

References (28)

1. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Cholesterol reduction yields clinical benefit: Impact of statin trials
7. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials
8. Lowering heart disease risk with cholesterol reduction: Evidence from observational studies and clinical trials
9. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
10. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
11. Small, dense low-density lipoprotein particles and coronary heart disease risk: A clear association with uncertain implications
12. The cholesterol facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute
13. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
14. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study
15. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
16. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
17. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
18. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation
19. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
20. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?
21. Cost of prevention: The case of lipid lowering
22. Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin Survival Study
23. Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S)
24. Medical economics in cardiovascular medicine
25. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
26. The West of Scotland Coronary Prevention Study: Economic benefit analysis of primary prevention with pravastatin
27. Drug treatment of lipid disorders
28. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study